BIOMAT Database Logo BIOMAT Database Logo

Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. 2022

Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong Province 264003, PR China.

The critical T790M secondary mutation in epidermal growth-factor receptor (EGFR) mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Herein, we identified 12 new 2,4-diaryl pyrimidine derivatives containing thiophene fragments as new selective third-generation EGFR inhibitors. Among them, Compound 6a showed good inhibitory activity against EGFR mutant cells with an IC50 value of 0.0022 ± 0.001 μM and was approximately 1730-fold less potent against EGFR WT cells (IC50: 4.499 ± 0.057 μM). Moreover, it strongly affected EGFR-mediated signaling pathways, attenuated tumor proliferation via the intrinsic mitochondrial apoptotic pathway, arrested the cell cycle at G0/G1 phase, and induced apoptosis in H1975 cells. It also displayed appropriate pharmacokinetic (PK) parameters with an oral bioavailability value of 33.57%. Additionally, in vivo studies confirmed that 6a suppressed tumor growth in an H1975 xenograft model (25 mg/kg/d, TGI: 90.24%). Overall, these results suggest that 6a could be a promising lead compound for overcoming the clinical EGFR T790M resistance of patients with non-small-cell lung cancers (NSCLCs).

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
April 2016, Journal of hematology & oncology,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
October 2016, Drugs of today (Barcelona, Spain : 1998),
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
June 2020, Cancer,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
July 2016, Journal of hematology & oncology,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Targeting the EGFR T790M mutation in non-small-cell lung cancer.
February 2017, Expert opinion on therapeutic targets,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.
March 2018, Drug discovery today,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.
June 2024, MedComm,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
February 2022, Cancer medicine,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
April 2023, Cancers,
Baijiao An, and Jian Liu, and Yangyang Fan, and Wenyan Nie, and Chunhua Yang, and Han Yao, and Wei Li, and Yin Zhang, and Xingshu Li, and Geng Tian
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
January 2017, Frontiers in oncology,
Copied contents to your clipboard!